newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

– Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK® but Not Sunitinib – – Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical